Sam Brusco, Associate Editor08.16.23
Tivic Health announced the research study it’s funding at the The Feinstein Institutes for Medical Research gained approval from the Institutional Review Board (IRB). Tivic has begun recruitment and enrollment for its novel, non-invasive bioelectronic approach to vagus nerve stimulation.
The first patients have already been enrolled as subjects. 20 individuals will undergo a new neurostimulation approach, and the Feinstein Institutes’ Institute of Bioelectronic Medicine researchers will perform data analysis and develop algorithms.
The vagus nerve is responsible for the regulation of organ function, carrying sensory information, controlling muscles, and influencing the immune system. Vagus nerve stimulation has been proven effective for conditions including treatment-resistant depression, epilepsy, and migraine.
The study aims to offer better targeting strategies for neurostimulation and more control over the types of physiologic effects that occur as a result of the stimulation.
“We’re excited for the proprietary value this work has the potential to deliver, as we continue to explore expanding Tivic’s non-invasive bioelectronic solutions to vagus nerve pathways and other clinical uses,” Jennifer Ernst, CEO at Tivic, told the press.
Tivic’s non-invasive, targeted stimulation approach is a treatment for inflammatory chronic health conditions. It’s first commercial product, ClearUP, is a U.S. Food and Drug Administration (FDA) approved and CE marked handheld bioelectronic sinus device.
In June, Tivic filed its first patent in vagus nerve stimulation with the U.S. Patent Office (USPTO), expanding its intellectual property portfolio into new clinical targets. The company currently has five issued U.S. patents, 96 claims, and 20 pending patents in the United States and abroad.
The first patients have already been enrolled as subjects. 20 individuals will undergo a new neurostimulation approach, and the Feinstein Institutes’ Institute of Bioelectronic Medicine researchers will perform data analysis and develop algorithms.
The vagus nerve is responsible for the regulation of organ function, carrying sensory information, controlling muscles, and influencing the immune system. Vagus nerve stimulation has been proven effective for conditions including treatment-resistant depression, epilepsy, and migraine.
The study aims to offer better targeting strategies for neurostimulation and more control over the types of physiologic effects that occur as a result of the stimulation.
“We’re excited for the proprietary value this work has the potential to deliver, as we continue to explore expanding Tivic’s non-invasive bioelectronic solutions to vagus nerve pathways and other clinical uses,” Jennifer Ernst, CEO at Tivic, told the press.
Tivic’s non-invasive, targeted stimulation approach is a treatment for inflammatory chronic health conditions. It’s first commercial product, ClearUP, is a U.S. Food and Drug Administration (FDA) approved and CE marked handheld bioelectronic sinus device.
In June, Tivic filed its first patent in vagus nerve stimulation with the U.S. Patent Office (USPTO), expanding its intellectual property portfolio into new clinical targets. The company currently has five issued U.S. patents, 96 claims, and 20 pending patents in the United States and abroad.